HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Can milnacipran used for neuropathic pain in patients with advanced cancer cause neuromuscular and somatosensory disorders?

AbstractBACKGROUND:
Milnacipran is one of the classes of drugs that are serotonin and norepinephrine reuptake inhibitors (SNRIs). It is a promising drug for the treatment of neuropathic pain in patients with advanced cancer. However, we found that neuromuscular and somatosensory disorders occurred when milnacipran was used as an adjuvant analgesic.
CASE REPORT:
A 66-year-old woman with a history of neuropathic pain was given 15 mg of milnacipran after dinner. The next morning she developed stiffness of the fingers, numbness in the mandible, and the soles of her feet felt swollen. Milnacipran was discontinued and her symptoms disappeared immediately. We managed this case, which was becoming severe, by discontinuing milnacipran on early detection of symptoms.
DISCUSSION:
This is the first report that demonstrates an adverse reaction of milnacipran when used as an analgesic adjuvant, and not as an antidepressant drug, for neuropathic pain in patients with advanced cancer. The analgesic effect of SNRIs will likely be used in the management of neuropathic pain in the future; however, clinicians should be aware of the early adverse reactions to these agents.
AuthorsSari Nakagawa, Yoshiaki Okamoto, Satoru Tsuneto, Hitoshi Tanimukai, Sho Goya, Yoichi Matsuda, Yumiko Oono, Mamiko Tsugane, Etsuko Uejima
JournalJournal of palliative medicine (J Palliat Med) Vol. 14 Issue 4 Pg. 403-5 (Apr 2011) ISSN: 1557-7740 [Electronic] United States
PMID21375395 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Cyclopropanes
  • Serotonin Uptake Inhibitors
  • Milnacipran
Topics
  • Aged
  • Contraindications
  • Cyclopropanes (therapeutic use)
  • Female
  • Humans
  • Milnacipran
  • Neoplasm Staging
  • Neoplasms (physiopathology)
  • Neuralgia (drug therapy)
  • Neuromuscular Diseases (chemically induced)
  • Selective Serotonin Reuptake Inhibitors (therapeutic use)
  • Somatosensory Disorders (chemically induced)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: